{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T15:49:41Z","timestamp":1790005781622,"version":"4.0.1"},"reference-count":238,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.addr.2021.113849","type":"journal-article","created":{"date-parts":[[2021,6,27]],"date-time":"2021-06-27T04:55:39Z","timestamp":1624769739000},"page":"113849","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"special_numbering":"C","title":["Advances in long-acting injectables, implants, and vaginal rings for contraception and HIV prevention"],"prefix":"10.1016","volume":"176","author":[{"given":"Sai Archana","family":"Krovi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3258-8713","authenticated-orcid":false,"given":"Leah M.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1509-5092","authenticated-orcid":false,"given":"Ellen","family":"Luecke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7478-8262","authenticated-orcid":false,"given":"Sharon L.","family":"Achilles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariane","family":"van der Straten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2021.113849_b0005","doi-asserted-by":"crossref","first-page":"e567","DOI":"10.1016\/S2214-109X(20)30060-7","article-title":"Trends in sexual activity and demand for and use of modern contraceptive methods in 74 countries: a retrospective analysis of nationally representative surveys","volume":"8","author":"Slaymaker","year":"2020","journal-title":"Lancet Glob. Health"},{"key":"10.1016\/j.addr.2021.113849_b0010","unstructured":"Contraceptive Use by Method 2019: Data Booklet United Nations Department of Economic and Social Affairs, 2019."},{"key":"10.1016\/j.addr.2021.113849_b0015","doi-asserted-by":"crossref","first-page":"e1152","DOI":"10.1016\/S2214-109X(20)30315-6","article-title":"Unintended pregnancy and abortion by income, region, and the legal status of abortion: estimates from a comprehensive model for 1990\u20132019","volume":"8","author":"Bearak","year":"2020","journal-title":"Lancet Glob. Health"},{"key":"10.1016\/j.addr.2021.113849_b0020","unstructured":"UNAIDS Global HIV & AIDS Statistics - 2020 fact sheet, 2020."},{"key":"10.1016\/j.addr.2021.113849_b0025","unstructured":"WHO Sexually Transmitted Infections (STIs) Fact Sheet, 2020."},{"key":"10.1016\/j.addr.2021.113849_b0030","doi-asserted-by":"crossref","first-page":"155","DOI":"10.5001\/omj.2011.38","article-title":"Patient medication adherence: measures in daily practice","volume":"26","author":"Jimmy","year":"2011","journal-title":"Oman Med. J."},{"key":"10.1016\/j.addr.2021.113849_b0035","doi-asserted-by":"crossref","first-page":"304","DOI":"10.4065\/mcp.2010.0575","article-title":"Medication adherence: WHO cares?","volume":"86","author":"Brown","year":"2011","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.addr.2021.113849_b0040","unstructured":"HPTN 084 Study Demonstrates Superiority of CAB LA to Oral FTC\/TDF for the Prevention of HIV, HIV Prevention Trials Network, 2020."},{"issue":"Suppl. 5","key":"10.1016\/j.addr.2021.113849_b0045","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/1471-0528.12852","article-title":"Beyond HIV microbicides: multipurpose prevention technology products","volume":"121","author":"Malcolm","year":"2014","journal-title":"BJOG"},{"key":"10.1016\/j.addr.2021.113849_b0050","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.contraception.2013.04.001","article-title":"The creeping Pearl: Why has the rate of contraceptive failure increased in clinical trials of combined hormonal contraceptive pills?","volume":"88","author":"Trussell","year":"2013","journal-title":"Contraception"},{"key":"10.1016\/j.addr.2021.113849_b0055","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1056\/NEJMra050100","article-title":"Adherence to medication","volume":"353","author":"Osterberg","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2021.113849_b0060","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/S1473-3099(18)30428-6","article-title":"Tenofovir 1% vaginal gel for prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"18","author":"Delany-Moretlwe","year":"2018","journal-title":"Lancet Infect. Dis."},{"issue":"Suppl 4","key":"10.1016\/j.addr.2021.113849_b0065","doi-asserted-by":"crossref","first-page":"e25298","DOI":"10.1002\/jia2.25298","article-title":"HIV pre-exposure prophylaxis for adolescent girls and young women in Africa: from efficacy trials to delivery","volume":"22","author":"Celum","year":"2019","journal-title":"J. Int. AIDS Soc."},{"key":"10.1016\/j.addr.2021.113849_b0070","doi-asserted-by":"crossref","first-page":"19146","DOI":"10.7448\/IAS.17.3.19146","article-title":"Perspectives on use of oral and vaginal antiretrovirals for HIV prevention: the VOICE-C qualitative study in Johannesburg, South Africa","volume":"17","author":"van der Straten","year":"2014","journal-title":"J. Int. AIDS Soc."},{"key":"10.1016\/j.addr.2021.113849_b0075","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa1402269","article-title":"Tenofovir-based preexposure prophylaxis for HIV infection among African women","volume":"372","author":"Marrazzo","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2021.113849_b0080","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1202614","article-title":"Preexposure prophylaxis for HIV infection among African women","volume":"367","author":"Van Damme","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2021.113849_b0085","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1097\/QAI.0000000000000993","article-title":"PrEP adherence patterns strongly affect individual HIV risk and observed efficacy in randomized clinical trials","volume":"72","author":"Dimitrov","year":"2016","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.addr.2021.113849_b0090","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1071\/SH11011","article-title":"Progress and challenges to male and female condom use in South Africa","volume":"9","author":"Beksinska","year":"2012","journal-title":"Sex. Health"},{"key":"10.1016\/j.addr.2021.113849_b0095","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1071\/SH11033","article-title":"Condoms in sub-Saharan Africa","volume":"9","author":"Maticka-Tyndale","year":"2012","journal-title":"Sex. Health"},{"key":"10.1016\/j.addr.2021.113849_b0100","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.2105\/AJPH.2017.303966","article-title":"HIV preexposure prophylaxis and condomless sex: disentangling personal values from public health priorities","volume":"107","author":"Calabrese","year":"2017","journal-title":"Am. J. Public Health"},{"key":"10.1016\/j.addr.2021.113849_b0105","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1097\/QAD.0000000000001262","article-title":"Using preexposure prophylaxis, losing condoms? Preexposure prophylaxis promotion may undermine safe sex","volume":"30","author":"Alaei","year":"2016","journal-title":"AIDS"},{"key":"10.1016\/j.addr.2021.113849_b0110","unstructured":"http:\/\/mpts101.org\/."},{"key":"10.1016\/j.addr.2021.113849_b0115","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2147\/IJWH.S185712","article-title":"\u201cWe are not the same\u201d: African women's view of multipurpose prevention products in the TRIO clinical study","volume":"11","author":"Shapley-Quinn","year":"2019","journal-title":"Int. J. Womens Health"},{"key":"10.1016\/j.addr.2021.113849_b0120","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.25064","article-title":"The cost-effectiveness of multi-purpose HIV and pregnancy prevention technologies in South Africa","volume":"21","author":"Quaife","year":"2018","journal-title":"J. Int AIDS Soc."},{"issue":"Suppl. 5","key":"10.1016\/j.addr.2021.113849_b0125","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/1471-0528.12844","article-title":"Aligning product development and user perspectives: social-behavioural dimensions of multipurpose prevention technologies","volume":"121","author":"Brady","year":"2014","journal-title":"BJOG"},{"key":"10.1016\/j.addr.2021.113849_b0130","unstructured":"Antibody infusions prevent acquisition of some HIV strains, NIH studies find, NIH, 2021."},{"key":"10.1016\/j.addr.2021.113849_b0135","article-title":"Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail","volume":"9","author":"Julg","year":"2017","journal-title":"Sci. Transl. Med."},{"issue":"Suppl.","key":"10.1016\/j.addr.2021.113849_b0140","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.1016\/j.antiviral.2013.09.027","article-title":"Antibody-based concepts for multipurpose prevention technologies","volume":"100","author":"Whaley","year":"2013","journal-title":"Antivir. Res."},{"key":"10.1016\/j.addr.2021.113849_b0145","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/s41591-019-0412-8","article-title":"Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic","volume":"25","author":"Caskey","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2021.113849_b0150","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1093\/biolre\/ioaa096","article-title":"Engineering monoclonal antibody-based contraception and multipurpose prevention technologies","volume":"103","author":"Anderson","year":"2020","journal-title":"Biol. Reprod."},{"key":"10.1016\/j.addr.2021.113849_b0155","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02465-16","article-title":"Pharmacokinetics and preliminary safety of pod-intravaginal rings delivering the monoclonal antibody VRC01-N for HIV prophylaxis in a macaque model","volume":"61","author":"Zhao","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2021.113849_b0160","doi-asserted-by":"crossref","DOI":"10.1097\/QAD.0000000000002934","article-title":"Broadly neutralizing antibody-mediated protection of macaques against repeated intravenous exposures to simian-human immunodeficiency virus","author":"Garber","year":"2021","journal-title":"AIDS"},{"key":"10.1016\/j.addr.2021.113849_b0165","article-title":"Basis and statistical design of the passive HIV-1 antibody mediated prevention (AMP) test-of-concept efficacy trials","volume":"9","author":"Gilbert","year":"2017","journal-title":"Stat. Commun. Infect. Dis."},{"key":"10.1016\/j.addr.2021.113849_b0170","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.chom.2018.12.001","article-title":"HIV-1 neutralizing antibody signatures and application to epitope-targeted vaccine design","volume":"25","author":"Bricault","year":"2019","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.addr.2021.113849_b0175","doi-asserted-by":"crossref","first-page":"e1006860","DOI":"10.1371\/journal.ppat.1006860","article-title":"Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections","volume":"14","author":"Wagh","year":"2018","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.addr.2021.113849_b0180","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1128\/JVI.03136-14","article-title":"Improving neutralization potency and breadth by combining broadly reactive HIV-1 antibodies targeting major neutralization epitopes","volume":"89","author":"Kong","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.addr.2021.113849_b0185","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.addr.2020.11.008","article-title":"Clinically established biodegradable long acting injectables: an industry perspective","volume":"167","author":"Nkanga","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2021.113849_b0190","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1007\/s10461-020-02808-2","article-title":"Acceptability of long-acting injectable cabotegravir (CAB LA) in HIV-uninfected individuals: HPTN 077","volume":"24","author":"Tolley","year":"2020","journal-title":"AIDS Behav."},{"key":"10.1016\/j.addr.2021.113849_b0195","doi-asserted-by":"crossref","first-page":"100303","DOI":"10.1016\/j.eclinm.2020.100303","article-title":"Safety and tolerability of injectable Rilpivirine LA in HPTN 076: A phase 2 HIV pre-exposure prophylaxis study in women","volume":"21","author":"Bekker","year":"2020","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.addr.2021.113849_b0200","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s40259-018-0295-0","article-title":"Subcutaneous administration of biotherapeutics: an overview of current challenges and opportunities","volume":"32","author":"Bittner","year":"2018","journal-title":"BioDrugs"},{"key":"10.1016\/j.addr.2021.113849_b0205","unstructured":"U.S. Food and Drug Administration (FDA). Depo-SubQ Provera 104 (Medroxyprogesterone Acetate) Injectable Suspension New Drug Application No.: 021583, U.S. Food and Drug Administration (FDA), 2014."},{"key":"10.1016\/j.addr.2021.113849_b0210","first-page":"1","article-title":"norethisterone enanthate given in two dosage regimens and depot-medroxyprogesterone acetate","volume":"28","author":"Multinational comparative clinical trial of long-acting injectable contraceptives","year":"1983","journal-title":"Final report, Contraception"},{"key":"10.1016\/j.addr.2021.113849_b0215","unstructured":"South Africa Demographic and Health Survey, 2016."},{"key":"10.1016\/j.addr.2021.113849_b0220","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.ejpb.2009.03.006","article-title":"Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment","volume":"72","author":"Baert","year":"2009","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2021.113849_b0225","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/infdis\/jiv528","article-title":"Selection of rilpivirine-resistant HIV-1 in a seroconverter from the SSAT 040 trial who received the 300-mg dose of long-acting rilpivirine (TMC278LA)","volume":"213","author":"Penrose","year":"2016","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.addr.2021.113849_b0230","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/COH.0000000000000168","article-title":"Formulation and pharmacology of long-acting cabotegravir","volume":"10","author":"Trezza","year":"2015","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.addr.2021.113849_b0235","doi-asserted-by":"crossref","first-page":"e472","DOI":"10.1016\/S2352-3018(20)30106-5","article-title":"Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial","volume":"7","author":"Landovitz","year":"2020","journal-title":"Lancet HIV"},{"key":"10.1016\/j.addr.2021.113849_b0240","unstructured":"Gilead Announces New Arm of HIV Women\u2019s Prevention Study to Evaluate the Investigational Long-Acting HIV-1 Capsid Inhibitor Lenacapavir in Addition to Descovy for PrEP\u00ae, Gilead, 2020."},{"key":"10.1016\/j.addr.2021.113849_b0245","unstructured":"R. Begley, J. L., M. Rhee, H. Dvory-Sobol, A. Chiu, S.K. West, J. Corpus, J. Ling, P. German, GS-6207 sustained delivery formulation supports 6-month dosing interval, Virtual AIDS (2020)."},{"key":"10.1016\/j.addr.2021.113849_b0250","unstructured":"B. Rogovoy, A. K., E. Volosova, R. Karapetian, I. Nikoulin, S. Sankar, G. Yakatan, V. Kan, N. Savchuk, K. Klumpp, R. Murphy, V. Bichko, Pre-clinical Development of Elsulfavirine\/VM1500A Long Acting Injectable Formulations, in: 16th European AIDS Conference, Milan, Italy, 2017."},{"key":"10.1016\/j.addr.2021.113849_b0255","unstructured":"E. Yakubova, A. M., A.V. Kravchenko, E. Ejova, E. Smolyarchuk, V. Kazey, S. Sankar, I. Nikoulin, S. Baranovskiy, A. Khvat, J. Remeeva, S. Corritori, N. Savchuk, I. Dukes, R. Murphy, Safety and PK Study of VM-1500A-LAI, a Novel Long-Acting Injectable Therapy for HIV, Virtual Conference on Retroviruses and Opportunistic Infections (CROI), Boston, MA, 2020."},{"key":"10.1016\/j.addr.2021.113849_b0260","series-title":"A Clinical Guide for Contraception","article-title":"Injectable Contraception","author":"Dorflinger","year":"2019"},{"key":"10.1016\/j.addr.2021.113849_b0265","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.contraception.2015.02.014","article-title":"Towards the development of a longer-acting injectable contraceptive: past research and current trends","volume":"92","author":"Halpern","year":"2015","journal-title":"Contraception"},{"key":"10.1016\/j.addr.2021.113849_b0270","doi-asserted-by":"crossref","first-page":"e0217333","DOI":"10.1371\/journal.pone.0217333","article-title":"Potential user interest in new long-acting contraceptives: results from a mixed methods study in Burkina Faso and Uganda","volume":"14","author":"Callahan","year":"2019","journal-title":"PLoS ONE"},{"key":"10.1016\/j.addr.2021.113849_b0275","doi-asserted-by":"crossref","unstructured":"S.R. d\u2019Arcangues C, Injectable Contraceptives, Fertility Control-Update and Trends, Springer-Verlag, Berlin, 1999, pp. 121\u2013149.","DOI":"10.1007\/978-3-642-86696-8_6"},{"key":"10.1016\/j.addr.2021.113849_b0280","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.contraception.2016.07.018","article-title":"Levonorgestrel butanoate intramuscular injection does not reliably suppress ovulation for 90 days in obese and normal-BMI women: a pilot study","volume":"95","author":"Edelman","year":"2017","journal-title":"Contraception"},{"key":"10.1016\/j.addr.2021.113849_b0285","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02817464. Study to Evaluate Suppression of Ovulation and Pharmacokinetics of Medroxyprogesterone Acetate Following Administration of TV-46046 in Women With Ovulatory Cycle. Accessed February 26, 2021."},{"key":"10.1016\/j.addr.2021.113849_b0290","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02456584. Pharmacodynamics and Pharmacokinetics Study of Existing DMPA Contraceptive Methods. Accessed February 26, 2021."},{"key":"10.1016\/j.addr.2021.113849_b0295","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.fertnstert.2020.11.002","article-title":"Clinical trial to evaluate pharmacokinetics and pharmacodynamics of medroxyprogesterone acetate after subcutaneous administration of Depo-Provera","volume":"115","author":"Halpern","year":"2021","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.addr.2021.113849_b0300","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics12111057","article-title":"Performance and stability of tenofovir alafenamide formulations within subcutaneous biodegradable implants for HIV Pre-Exposure Prophylaxis (PrEP)","volume":"12","author":"Li","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.addr.2021.113849_b0305","unstructured":"FDA Approves First Extended-Release, Injectable Drug Regimen for Adults Living with HIV, Food & Drug Administration, 2021."},{"key":"10.1016\/j.addr.2021.113849_b0310","article-title":"for the HPTN 083 Study Team, HPTN083 interim results: pre-exposure prophylaxis (PrEP) containing long-acting injectable cabotegravir (CAB-LA) is safe and highly effective for cisgender men and transgender women who have sex with men (MSM, TGW)","author":"Landovitz","year":"2020","journal-title":"Virtual AIDS"},{"key":"10.1016\/j.addr.2021.113849_b0315","unstructured":"ViiV Healthcare receives FDA Breakthrough Therapy Designation for investigational, long-acting cabotegravir for HIV prevention, ViiV Healthcare, 2020."},{"key":"10.1016\/j.addr.2021.113849_b0320","unstructured":"Viriom Announces Initiation of Phase 2 Study Investigating Efficacy of Intramuscular Long-Acting Injectable Nanoformulation of VM1500A in HIV-Infected Patients, Viriom, 2020."},{"key":"10.1016\/j.addr.2021.113849_b0325","doi-asserted-by":"crossref","first-page":"106220","DOI":"10.1016\/j.ijantimicag.2020.106220","article-title":"Long-acting drugs and formulations for the treatment and prevention of HIV infection","volume":"57","author":"Flexner","year":"2021","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.addr.2021.113849_b0330","doi-asserted-by":"crossref","DOI":"10.3390\/ph12020062","article-title":"Long-acting anti-HIV drugs targeting HIV-1 reverse transcriptase and integrase","volume":"12","author":"Singh","year":"2019","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.addr.2021.113849_b0335","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1038\/s41467-019-09354-z","article-title":"Semi-solid prodrug nanoparticles for long-acting delivery of water-soluble antiretroviral drugs within combination HIV therapies","volume":"10","author":"Hobson","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2021.113849_b0340","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1093\/jac\/dkw042","article-title":"A long-acting formulation of the integrase inhibitor raltegravir protects humanized BLT mice from repeated high-dose vaginal HIV challenges","volume":"71","author":"Kovarova","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.addr.2021.113849_b0345","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ejpb.2018.04.009","article-title":"Towards a Maraviroc long-acting injectable nanoformulation","volume":"138","author":"Tatham","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2021.113849_b0350","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1038\/s41591-019-0560-x","article-title":"A highly potent long-acting small-molecule HIV-1 capsid inhibitor with efficacy in a humanized mouse model","volume":"25","author":"Yant","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2021.113849_b0355","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1038\/s41563-020-0674-z","article-title":"A year-long extended release nanoformulated cabotegravir prodrug","volume":"19","author":"Kulkarni","year":"2020","journal-title":"Nat. Mater."},{"key":"10.1016\/j.addr.2021.113849_b0360","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jconrel.2020.11.030","article-title":"Fully synthetic injectable depots with high drug content and tunable pharmacokinetics for long-acting drug delivery","volume":"329","author":"Ho","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2021.113849_b0365","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1038\/s41467-021-23668-x","article-title":"Lipophilic nanocrystal prodrug-release defines the extended pharmacokinetic profiles of a year-long cabotegravir","volume":"12","author":"Gautam","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2021.113849_b0370","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jconrel.2019.09.001","article-title":"Creation of a long-acting rilpivirine prodrug nanoformulation","volume":"311\u2013312","author":"Hilaire","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2021.113849_b0375","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/s41467-018-02885-x","article-title":"Creation of a long-acting nanoformulated dolutegravir","volume":"9","author":"Sillman","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2021.113849_b0380","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02320-20","article-title":"A Concept Evaluation Study of a New Combination Bictegravir plus Tenofovir Alafenamide Nanoformulation with Prolonged Sustained-Drug-Release Potency for HIV-1 Preexposure Prophylaxis","volume":"65","author":"Mandal","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2021.113849_b0385","unstructured":"https:\/\/www.hvtn.org\/en\/community\/community-compass\/vol20-issue1\/phase-1-broadly-neutralizing-antibody-efforts.html."},{"key":"10.1016\/j.addr.2021.113849_b0390","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1097\/QAD.0000000000001392","article-title":"Drug interactions between hormonal contraceptives and antiretrovirals","volume":"31","author":"Nanda","year":"2017","journal-title":"AIDS"},{"key":"10.1016\/j.addr.2021.113849_b0395","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1128\/AAC.04701-14","volume":"59","author":"Luque","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2021.113849_b0400","unstructured":"Drug Interactions Between Hormonal Contraceptive Methods and Anti-Retroviral Medications Used to Treat HIV. https:\/\/www.usaid.gov\/sites\/default\/files\/documents\/1864\/HC_ART-Brief.pdf. Accessed May 24, 2021. , 2014."},{"key":"10.1016\/j.addr.2021.113849_b0405","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.contraception.2007.10.002","article-title":"Safety and tolerability of depot medroxyprogesterone acetate among HIV-infected women on antiretroviral therapy: ACTG A5093","volume":"77","author":"Watts","year":"2008","journal-title":"Contraception"},{"key":"10.1016\/j.addr.2021.113849_b0410","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1097\/QAD.0000000000000493","article-title":"Preexposure prophylaxis is efficacious for HIV-1 prevention among women using depot medroxyprogesterone acetate for contraception","volume":"28","author":"Heffron","year":"2014","journal-title":"AIDS"},{"key":"10.1016\/j.addr.2021.113849_b0415","doi-asserted-by":"crossref","first-page":"e25094","DOI":"10.1002\/jia2.25094","article-title":"The Tablets, Ring, Injections as Options (TRIO) study: what young African women chose and used for future HIV and pregnancy prevention","volume":"21","author":"van der Straten","year":"2018","journal-title":"J. Int. AIDS Soc."},{"key":"10.1016\/j.addr.2021.113849_b0420","unstructured":"https:\/\/www.rti.org\/publication\/preventing-hiv-sub-saharan-africa-0\/fulltext.pdf."},{"key":"10.1016\/j.addr.2021.113849_b0425","unstructured":"https:\/\/www.rti.org\/publication\/preventing-hiv-sub-saharan-africa\/fulltext.pdf."},{"key":"10.1016\/j.addr.2021.113849_b0430","unstructured":"http:\/\/theimpt.org\/resource-results\/51-technical-brief\/1290-trio-injections-research-brief-what-end-users-think."},{"key":"10.1016\/j.addr.2021.113849_b0435","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1517\/17425247.3.2.261","article-title":"Drug delivery from ocular implants","volume":"3","author":"Yasukawa","year":"2006","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.addr.2021.113849_b0440","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.addr.2006.07.026","article-title":"Intraocular implants for extended drug delivery: therapeutic applications","volume":"58","author":"Bourges","year":"2006","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2021.113849_b0445","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ejpb.2015.08.007","article-title":"A controlled antibiotic release system to prevent orthopedic-implant associated infections: an in vitro study","volume":"96","author":"Gimeno","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2021.113849_b0450","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ijcard.2004.01.021","article-title":"Drug-eluting stents: results, promises and problems","volume":"99","author":"van der Hoeven","year":"2005","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.addr.2021.113849_b0455","first-page":"615","article-title":"Current perspectives on intrathecal drug delivery","volume":"7","author":"Bottros","year":"2014","journal-title":"J. Pain Res."},{"key":"10.1016\/j.addr.2021.113849_b0460","first-page":"403","article-title":"Recent advances in ceramic implants as drug delivery systems for biomedical applications","volume":"3","author":"Colilla","year":"2008","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.addr.2021.113849_b0465","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.3390\/polym10121379","article-title":"Implantable polymeric drug delivery devices: classification, manufacture, materials, and clinical applications","volume":"10","author":"Stewart","year":"2018","journal-title":"Polymers"},{"key":"10.1016\/j.addr.2021.113849_b0470","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2014.02.006","article-title":"Evolution of implantable and insertable drug delivery systems","volume":"181","author":"Kleiner","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2021.113849_b0475","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1021\/jacs.5b09974","article-title":"Emerging Frontiers in Drug Delivery","volume":"138","author":"Tibbitt","year":"2016","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.addr.2021.113849_b0480","unstructured":"https:\/\/www.nexplanon.com\/."},{"key":"10.1016\/j.addr.2021.113849_b0485","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.clinthera.2013.03.011","article-title":"A randomized, open-label, multicenter, 4-week study to evaluate the tolerability and pharmacokinetics of ITCA 650 in patients with type 2 diabetes","volume":"35","author":"Henry","year":"2013","journal-title":"Clin. Ther."},{"key":"10.1016\/j.addr.2021.113849_b0490","unstructured":"https:\/\/www.intarcia.com\/pipeline-technology\/itca-650.html."},{"key":"10.1016\/j.addr.2021.113849_b0495","unstructured":"http:\/\/www.diabetesincontrol.com\/wp-content\/uploads\/PDF\/ntarcia_platform_technology.pdf."},{"key":"10.1016\/j.addr.2021.113849_b0500","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1128\/AAC.00656-15","article-title":"Pharmacokinetics of Long-Acting Tenofovir Alafenamide (GS-7340) Subdermal Implant for HIV Prophylaxis","volume":"59","author":"Gunawardana","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2021.113849_b0505","doi-asserted-by":"crossref","first-page":"e01893","DOI":"10.1128\/AAC.01893-19","article-title":"A subcutaneous implant of tenofovir alafenamide fumarate causes local inflammation and tissue necrosis in rabbits and macaques","volume":"64","author":"Su","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2021.113849_b0510","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jconrel.2018.08.010","article-title":"Transcutaneously refillable nanofluidic implant achieves sustained level of tenofovir diphosphate for HIV pre-exposure prophylaxis","volume":"286","author":"Chua","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2021.113849_b0515","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1056\/NEJMcp1608736","article-title":"Long-acting reversible contraception","volume":"376","author":"Curtis","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2021.113849_b0520","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0002-9378(99)70120-1","article-title":"The mechanism of action of hormonal contraceptives and intrauterine contraceptive devices","volume":"181","author":"Rivera","year":"1999","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.addr.2021.113849_b0525","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/j.fertnstert.2008.02.140","article-title":"Safety and efficacy of a single-rod etonogestrel implant (Implanon): results from 11 international clinical trials","volume":"91","author":"Darney","year":"2009","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.addr.2021.113849_b0530","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.bpobgyn.2019.12.002","article-title":"Long-acting reversible contraceptive (LARCs) methods","volume":"66","author":"Bahamondes","year":"2020","journal-title":"Best Pract. Res. Clin. Obstet. Gynaecol."},{"key":"10.1016\/j.addr.2021.113849_b0535","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1080\/13625180801942754","article-title":"The contraceptive efficacy of Implanon\u00ae: a review of clinical trials and marketing experience","volume":"13","author":"Graesslin","year":"2008","journal-title":"Eur. J. Contracept. Reprod. Health Care"},{"key":"10.1016\/j.addr.2021.113849_b0540","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/13625180801959931","article-title":"The effects of Implanon\u00ae on menstrual bleeding patterns","volume":"13","author":"Mansour","year":"2008","journal-title":"Eur. J. Contracept. Reprod. Health Care"},{"key":"10.1016\/j.addr.2021.113849_b0545","unstructured":"FDA review panel gives thumbs up to Norplant, Washington memo, (1989) 3-5."},{"key":"10.1016\/j.addr.2021.113849_b0550","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2307\/1966240","article-title":"Norplant: reversible implant contraception","volume":"11","author":"Sivin","year":"1980","journal-title":"Stud. Fam. Plan."},{"key":"10.1016\/j.addr.2021.113849_b0555","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1016\/S0002-9378(12)91812-8","article-title":"Hormonal implants: contraception for a new century","volume":"170","author":"Darney","year":"1994","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.addr.2021.113849_b0560","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2307\/1966493","article-title":"International experience with norplant and norplant-2 contraceptives","volume":"19","author":"Sivin","year":"1988","journal-title":"Stud. Fam. Plan."},{"key":"10.1016\/j.addr.2021.113849_b0565","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/0010-7824(91)90030-J","article-title":"Clinical trial with 3-keto-desogestrel subdermal implants","volume":"44","author":"D\u00edaz","year":"1991","journal-title":"Contraception"},{"key":"10.1016\/j.addr.2021.113849_b0570","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1128\/AAC.00976-10","article-title":"Combinatorial approaches to the prevention and treatment of HIV-1 infection","volume":"55","author":"Pirrone","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2021.113849_b0575","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1007\/s13224-011-0066-z","article-title":"Implanon: subdermal single rod contraceptive implant","volume":"61","author":"Bhatia","year":"2011","journal-title":"J. Obstet. Gynaecol. India"},{"key":"10.1016\/j.addr.2021.113849_b0580","unstructured":"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/021529s018lbl.pdf."},{"key":"10.1016\/j.addr.2021.113849_b0585","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1093\/oxfordjournals.humrep.a138341","article-title":"Contraception: contraception with NORPLANT\u00ae implants*","volume":"9","author":"Sivin","year":"1994","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.addr.2021.113849_b0590","unstructured":"U.S.F.a.D. Administration, Highlights of Prescribing Information JADELLE, 2016."},{"key":"10.1016\/j.addr.2021.113849_b0595","doi-asserted-by":"crossref","first-page":"100039","DOI":"10.1016\/j.conx.2020.100039","article-title":"Levonorgestrel release rates measured through analysis of two-rod contraceptive explants","volume":"2","author":"Fuchs","year":"2020","journal-title":"Contracept. X"},{"key":"10.1016\/j.addr.2021.113849_b0600","unstructured":"https:\/\/extranet.who.int\/pqweb\/medicine\/3997."},{"key":"10.1016\/j.addr.2021.113849_b0605","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0015-0282(16)55150-4","article-title":"Evaluation of a 1-year levonorgestrel-releasing contraceptive implant: side effects, release rates, and biodegradability","volume":"58","author":"Darney","year":"1992","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.addr.2021.113849_b0610","unstructured":"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/021529s004lbl.pdf."},{"key":"10.1016\/j.addr.2021.113849_b0615","unstructured":"https:\/\/pactr.samrc.ac.za\/TrialDisplay.aspx?TrialID=3584."},{"key":"10.1016\/j.addr.2021.113849_b0620","unstructured":"G.J. Gatto, S.A. Krovi, L.M. Johnson, Z.R. Demkovich, M.A. Marzinke, E. Luecke, A.v.d. Straten, Sustained 6-month Release Of Tenofovir Alafenamide (TAF) From A Biodegradable Implant For Long-acting (LA)-HIV Pre-Exposure Prophylaxis (PrEP), Poster 967, Virtual CRS, 2020."},{"key":"10.1016\/j.addr.2021.113849_b0625","unstructured":"I. Massud, A. Krovi, S. Ruone, A. Holder, J. Gary, P. Mills, F. Deyounks, R. Johnson, L. Johnson, G. Gatto, E. Luecke, W. Heneine, G. Garc\u03afa-Lerma, C. Dobard, A.v.d. Straten, Pharmacokinetics and safety of long-acting tenofovir alafenamide implants in macaques for HIV prevention, Poster PEA0087, Virtual IAS, 2020"},{"key":"10.1016\/j.addr.2021.113849_b0630","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.jconrel.2020.12.024","article-title":"Design and testing of a cabotegravir implant for HIV prevention","volume":"330","author":"Karunakaran","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2021.113849_b0635","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jconrel.2019.05.037","article-title":"2-Hydroxypropyl-\u03b2-cyclodextrin-enhanced pharmacokinetics of cabotegravir from a nanofluidic implant for HIV pre-exposure prophylaxis","volume":"306","author":"Pons-Faudoa","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2021.113849_b0640","unstructured":"R. Matthews, First-in-human trial of MK-8591-eluting implants demonstrates concentrations suitable for HIV prophylaxis for at least one year, International AIDS Society (IAS),Mexico City, Mexico, 2019."},{"key":"10.1016\/j.addr.2021.113849_b0645","unstructured":"L. Li, S.A. Krovi, C. Norton, E. Luecke, Z. Demkovich, P. Johnson, C. Areson, G. Jimenez, A. van der Straten, L.M. Johnson, Biodegradable Implant for Delivery of Antiretroviral (ARV) and Hormonal Contraceptive, Virtual CROI, 2020."},{"key":"10.1016\/j.addr.2021.113849_b0650","article-title":"Long-acting co-formulated biodegradable implant for HIV prevention and contraception, Abstract 2107","author":"Li","year":"2021","journal-title":"Virtual CROI"},{"key":"10.1016\/j.addr.2021.113849_b0655","unstructured":"E. Schlesinger, Rothrock, G.D., McGowan, I., van der Straten, A., Desai, T., Thin Film Polymer Device for Long-Acting Antiretroviral HIV PrEP, Preclinical Form and Formulation for Drug Delivery Gordon Research Conference, Waterville Valley, NH, 2015."},{"key":"10.1016\/j.addr.2021.113849_b0660","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1007\/s11095-016-1904-6","article-title":"Biodegradable, thin-film polymer device as a long-acting implant delivering tenofovir alafenamide fumarate for HIV pre-exposure prophylaxis","volume":"33","author":"Schlesinger","year":"2016","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2021.113849_b0665","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.antiviral.2015.11.009","article-title":"Tenofovir alafenamide: a novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus","volume":"125","author":"Ray","year":"2016","journal-title":"Antivir. Res."},{"key":"10.1016\/j.addr.2021.113849_b0670","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.3390\/pharmaceutics12111057","article-title":"Performance and stability of tenofovir alafenamide formulations within subcutaneous biodegradable implants for HIV Pre-Exposure Prophylaxis (PrEP)","volume":"12","author":"Li","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.addr.2021.113849_b0675","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119623","article-title":"Trans-urocanic acid enhances tenofovir alafenamide stability for long-acting HIV applications","volume":"587","author":"Sizovs","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2021.113849_b0680","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.569373","article-title":"Multispecies evaluation of a long-acting tenofovir alafenamide subdermal implant for HIV prophylaxis","volume":"11","author":"Gunawardana","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.addr.2021.113849_b0685","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1089\/aid.2021.0028","article-title":"Tenofovir alafenamide for HIV prevention: review of the proceedings from the gates foundation long-acting TAF product development meeting","volume":"37","author":"Romano","year":"2021","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"10.1016\/j.addr.2021.113849_b0690","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s11095-020-2777-2","article-title":"Design of a drug-eluting subcutaneous implant of the antiretroviral tenofovir alafenamide fumarate","volume":"37","author":"Simpson","year":"2020","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2021.113849_b0695","doi-asserted-by":"crossref","unstructured":"F.P. Pons-Faudoa, A. Sizovs, K.A. Shelton, Z. Momin, L.R. Bushman, C.Y.X. Chua, J.E. Nichols, T. Hawkins, J.F. Rooney, M.A. Marzinke, J.T. Kimata, P.L. Anderson, P.N. Nehete, R.C. Arduino, M. Ferrari, K.J. Sastry, A. Grattoni, Preventive efficacy of a tenofovir alafenamide fumarate nanofluidic implant in SHIV-challenged nonhuman primates, Adv. Ther., (2020) 2020.2005.2013.091694.","DOI":"10.1101\/2020.05.13.091694"},{"key":"10.1016\/j.addr.2021.113849_b0700","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics11070315","article-title":"Characterization of a Reservoir-Style Implant for Sustained Release of Tenofovir Alafenamide (TAF) for HIV Pre-Exposure Prophylaxis (PrEP)","volume":"11","author":"Johnson","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.addr.2021.113849_b0705","unstructured":"G.J. Gatto, Brand, R.M., Girouard, N., Li, L., Johnosn, L., Marzinke, M.A., Krogstad, E., Siegel, A., Demkovich, Z., Luecke, E., van der Straten, A., Development of an End-User Informed Tenofovir Alafenamide (TAF) Implant for Long-Acting (LA)-HIV Pre-exposure Prophylaxis (PrEP), HIVR4PMadrid, Spain, 2018."},{"key":"10.1016\/j.addr.2021.113849_b0710","unstructured":"I. Massud, K. Nishiura, S. Ruone, A. Krovi, A. Holder, J. Gary, P. Mills, J. Mitchell, G. Khalil, L. Li, L. Johnson, E. Luecke, W. Heneine, G. Garcia-Lerma, C. Dobard, A.v.d. Straten, High protection against vaginal SHIV infection in macaques by a biodegradable implant releasing tenofovir alafenamide, Virtual HIVR4PVirtual, 2021."},{"key":"10.1016\/j.addr.2021.113849_b0715","doi-asserted-by":"crossref","first-page":"e01058","DOI":"10.1128\/AAC.01058-18","article-title":"Extended-Duration MK-8591-Eluting Implant as a Candidate for HIV Treatment and Prevention","volume":"62","author":"Barrett","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2021.113849_b0720","article-title":"Next-Generation Islatravir Implants Projected to Provide Yearly HIV Prophylaxis, Oral Abstract 88","author":"Matthews","year":"2021","journal-title":"Virtual CROI"},{"key":"10.1016\/j.addr.2021.113849_b0725","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1592\/phco.29.8.924","article-title":"Lack of effect of tenofovir disoproxil fumarate on pharmacokinetics of hormonal contraceptives","volume":"29","author":"Kearney","year":"2009","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.addr.2021.113849_b0730","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.contraception.2014.10.008","article-title":"Sino-implant (II)\u00ae continuation and effect of concomitant tenofovir disoproxil fumarate-emtricitabine use on plasma levonorgestrel concentrations among women in Bondo, Kenya","volume":"91","author":"Todd","year":"2015","journal-title":"Contraception"},{"key":"10.1016\/j.addr.2021.113849_b0735","doi-asserted-by":"crossref","unstructured":"W. Ankrom, D. Jonathan, D. Rudd, S. Zhang, K. Fillgrove, K. Gravesande, R. Matthews, D. Brimhall, A. Stoch, M. Iwamoto, MK-8591 Does Not Alter the Pharmacokinetics of the Oral Contraceptives Ethinyl Estradiol and Levonorgestrel, Abstract 551, ID Week 2018, 2018.","DOI":"10.1093\/ofid\/ofy210.559"},{"key":"10.1016\/j.addr.2021.113849_b0740","doi-asserted-by":"crossref","DOI":"10.7573\/dic.2020-5-9","article-title":"Potential risk of drug-drug interactions with hormonal contraceptives and antiretrovirals: prevalence in women living with HIV","volume":"9","author":"Murray","year":"2020","journal-title":"Drugs Context"},{"key":"10.1016\/j.addr.2021.113849_b0745","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1097\/QAD.0000000000001591","article-title":"Efavirenz decreases etonogestrel exposure: a pharmacokinetic evaluation of implantable contraception with antiretroviral therapy","volume":"31","author":"Chappell","year":"2017","journal-title":"AIDS"},{"key":"10.1016\/j.addr.2021.113849_b0750","doi-asserted-by":"crossref","first-page":"19484","DOI":"10.7448\/IAS.17.4.19484","article-title":"Efavirenz- but not nevirapine-based antiretroviral therapy decreases exposure to the levonorgestrel released from a sub-dermal contraceptive implant","volume":"17","author":"Scarsi","year":"2014","journal-title":"J. Int. AIDS Soc."},{"key":"10.1016\/j.addr.2021.113849_b0755","doi-asserted-by":"crossref","first-page":"18448","DOI":"10.7448\/IAS.16.1.18448","article-title":"Effect of concurrent use of anti-retroviral therapy and levonorgestrel sub-dermal implant for contraception on CD4 counts: a prospective cohort study in Kenya","volume":"16","author":"Hubacher","year":"2013","journal-title":"J. Int. AIDS Soc."},{"key":"10.1016\/j.addr.2021.113849_b0760","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S0022-3565(25)08541-6","article-title":"On the absorption of drugs and poisons through the vagina","volume":"10","author":"Macht","year":"1918","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.addr.2021.113849_b0765","doi-asserted-by":"crossref","first-page":"e0224898","DOI":"10.1371\/journal.pone.0224898","article-title":"Vaginal ring acceptability and related preferences among women in low- and middle-income countries: a systematic review and narrative synthesis","volume":"14","author":"Griffin","year":"2019","journal-title":"PLoS ONE"},{"issue":"Suppl. 1","key":"10.1016\/j.addr.2021.113849_b0770","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/j.antiviral.2010.09.003","article-title":"Advances in microbicide vaginal rings","volume":"88","author":"Malcolm","year":"2010","journal-title":"Antivir. Res."},{"key":"10.1016\/j.addr.2021.113849_b0775","first-page":"62","article-title":"State of the art in intravaginal ring technology for topical prophylaxis of HIV infection","volume":"14","author":"Kiser","year":"2012","journal-title":"AIDS Rev."},{"key":"10.1016\/j.addr.2021.113849_b0780","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0168-3659(03)00178-0","article-title":"Influence of silicone elastomer solubility and diffusivity on the in vitro release of drugs from intravaginal rings","volume":"90","author":"Malcolm","year":"2003","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2021.113849_b0785","first-page":"Cd003552","article-title":"Skin patch and vaginal ring versus combined oral contraceptives for contraception","volume":"2013","author":"Lopez","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.addr.2021.113849_b0790","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ejps.2009.11.007","article-title":"Segmented polyurethane intravaginal rings for the sustained combined delivery of antiretroviral agents dapivirine and tenofovir","volume":"39","author":"Johnson","year":"2010","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.addr.2021.113849_b0795","doi-asserted-by":"crossref","first-page":"785","DOI":"10.4155\/tde.10.74","article-title":"Controlled-release vaginal ring drug-delivery systems: a key strategy for the development of effective HIV microbicides","volume":"1","author":"Fetherston","year":"2010","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.addr.2021.113849_b0800","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.ejps.2012.12.002","article-title":"A silicone elastomer vaginal ring for HIV prevention containing two microbicides with different mechanisms of action","volume":"48","author":"Fetherston","year":"2013","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.addr.2021.113849_b0805","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1002\/jps.23208","article-title":"An intravaginal ring for the simultaneous delivery of multiple drugs","volume":"101","author":"Baum","year":"2012","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2021.113849_b0810","doi-asserted-by":"crossref","first-page":"e88509","DOI":"10.1371\/journal.pone.0088509","article-title":"Engineering a segmented dual-reservoir polyurethane intravaginal ring for simultaneous prevention of HIV transmission and unwanted pregnancy","volume":"9","author":"Clark","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.addr.2021.113849_b0815","doi-asserted-by":"crossref","first-page":"3994","DOI":"10.1128\/AAC.00547-13","article-title":"Pharmacokinetics of a multipurpose pod-intravaginal ring simultaneously delivering five drugs in an ovine model","volume":"57","author":"Moss","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2021.113849_b0820","unstructured":"http:\/\/www.ornibel.nl\/."},{"key":"10.1016\/j.addr.2021.113849_b0825","doi-asserted-by":"crossref","first-page":"839","DOI":"10.2174\/138920010794479646","article-title":"Is the vagina an adequate route for the administration of hormonal contraceptives?","volume":"11","author":"Lete","year":"2010","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.addr.2021.113849_b0830","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2147\/IJWH.S6162","article-title":"Examining the efficacy, safety, and patient acceptability of the combined contraceptive vaginal ring (NuvaRing)","volume":"2","author":"Wieder","year":"2010","journal-title":"Int. J. Womens Health"},{"key":"10.1016\/j.addr.2021.113849_b0835","first-page":"618","article-title":"Segesterone Acetate and Ethinyl Estradiol Vaginal Ring (Annovera) for Contraception","volume":"101","author":"Lee","year":"2020","journal-title":"Am. Fam. Physician"},{"key":"10.1016\/j.addr.2021.113849_b0840","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1080\/13625187.2017.1413179","article-title":"Pharmacokinetic bioequivalence, safety and acceptability of Ornibel(\u00ae), a new polymer composition contraceptive vaginal ring (etonogestrel\/ethinylestradiol 11.00\/3.474 mg) compared with Nuvaring(\u00ae) (etonogestrel\/ethinylestradiol 11.7\/2.7 mg)","volume":"22","author":"Algorta","year":"2017","journal-title":"Eur. J. Contracept. Reprod. Health Care"},{"key":"10.1016\/j.addr.2021.113849_b0845","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.contraception.2010.05.016","article-title":"Progesterone vaginal ring for contraceptive use during lactation","volume":"82","author":"Nath","year":"2010","journal-title":"Contraception"},{"key":"10.1016\/j.addr.2021.113849_b0850","unstructured":"https:\/\/ir.darebioscience.com\/events-presentations."},{"key":"10.1016\/j.addr.2021.113849_b0855","unstructured":"https:\/\/www.businesswire.com\/news\/home\/20200113005274\/en\/. Accessed May 25, 2021."},{"key":"10.1016\/j.addr.2021.113849_b0860","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT03598088."},{"key":"10.1016\/j.addr.2021.113849_b0865","first-page":"685","article-title":"A pilot safety and tolerability study of a nonhormonal vaginal contraceptive ring","volume":"54","author":"Del Priore","year":"2009","journal-title":"J. Reprod. Med."},{"key":"10.1016\/j.addr.2021.113849_b0870","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.contraception.2012.08.038","article-title":"Vaginal ring delivery of selective progesterone receptor modulators for contraception","volume":"87","author":"Jensen","year":"2013","journal-title":"Contraception"},{"key":"10.1016\/j.addr.2021.113849_b0875","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/sifp.12046","article-title":"Do Women Find the Progesterone Vaginal Ring Acceptable? Findings from Kenya, Nigeria, and Senegal","volume":"49","author":"RamaRao","year":"2018","journal-title":"Stud. Fam. Plan."},{"key":"10.1016\/j.addr.2021.113849_b0880","unstructured":"https:\/\/ir.darebioscience.com\/static-files\/b7432ec0-13ef-41d6-8e87-2b23fb0cd2f2."},{"key":"10.1016\/j.addr.2021.113849_b0885","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.contraception.2014.08.006","article-title":"A randomized study on pharmacodynamic effects of vaginal rings delivering the progesterone receptor modulator ulipristal acetate: research for a novel estrogen-free, method of contraception","volume":"90","author":"Huang","year":"2014","journal-title":"Contraception"},{"key":"10.1016\/j.addr.2021.113849_b0890","unstructured":"R.N.Y. Sitruk-Ware, NY, US), Tsong, Yun-yen (North Caldwell, NJ, US), Sustained Release Compositions Containing Progesterone Receptor Modulators, Application No. 20080199511, Laboratoire HRA Pharma (Paris, FR), United States, 2008."},{"key":"10.1016\/j.addr.2021.113849_b0895","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1016\/S2352-3018(20)30304-0","article-title":"Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study","volume":"8","author":"Baeten","year":"2021","journal-title":"Lancet HIV"},{"key":"10.1016\/j.addr.2021.113849_b0900","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa1602046","article-title":"Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women","volume":"375","author":"Nel","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2021.113849_b0905","doi-asserted-by":"crossref","first-page":"e498","DOI":"10.1016\/S2352-3018(19)30145-6","article-title":"Tenofovir disoproxil fumarate intravaginal ring for HIV pre-exposure prophylaxis in sexually active women: a phase 1, single-blind, randomised, controlled trial","volume":"6","author":"Keller","year":"2019","journal-title":"Lancet HIV"},{"key":"10.1016\/j.addr.2021.113849_b0910","doi-asserted-by":"crossref","first-page":"e0199778","DOI":"10.1371\/journal.pone.0199778","article-title":"Randomized, placebo controlled phase I trial of safety, pharmacokinetics, pharmacodynamics and acceptability of tenofovir and tenofovir plus levonorgestrel vaginal rings in women","volume":"13","author":"Thurman","year":"2018","journal-title":"PLoS ONE"},{"key":"10.1016\/j.addr.2021.113849_b0915","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1007\/s11095-017-2224-1","article-title":"A Dose Ranging Pharmacokinetic Evaluation of IQP-0528 Released from Intravaginal Rings in Non-Human Primates","volume":"34","author":"Su","year":"2017","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2021.113849_b0920","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1128\/AAC.01529-13","article-title":"MIV-150-containing intravaginal rings protect macaque vaginal explants against SHIV-RT infection","volume":"58","author":"Ouattara","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2021.113849_b0925","doi-asserted-by":"crossref","first-page":"150ra123","DOI":"10.1126\/scitranslmed.3003936","article-title":"An intravaginal ring that releases the NNRTI MIV-150 reduces SHIV transmission in macaques","volume":"4","author":"Singer","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.addr.2021.113849_b0930","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.ijpharm.2016.07.051","article-title":"Matrix and reservoir-type multipurpose vaginal rings for controlled release of dapivirine and levonorgestrel","volume":"511","author":"Boyd","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2021.113849_b0935","article-title":"Pharmacokinetics, safety, and vaginal bleeding associated with continuous versus cyclic 90-day use of dapivirine and levonorgestrel vaginal rings for multipurpose prevention of HIV and pregnancy","author":"Achilles","year":"2021","journal-title":"Virtual HIVR4P"},{"key":"10.1016\/j.addr.2021.113849_b0940","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jconrel.2015.06.018","article-title":"A novel intravaginal ring to prevent HIV-1, HSV-2, HPV, and unintended pregnancy","volume":"213","author":"Ugaonkar","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2021.113849_b0945","doi-asserted-by":"crossref","first-page":"e0185946","DOI":"10.1371\/journal.pone.0185946","article-title":"Novel multipurpose pod-intravaginal ring for the prevention of HIV, HSV, and unintended pregnancy: pharmacokinetic evaluation in a macaque model","volume":"12","author":"Smith","year":"2017","journal-title":"PLoS ONE"},{"key":"10.1016\/j.addr.2021.113849_b0950","unstructured":"https:\/\/projectreporter.nih.gov\/project_info_description.cfm?aid=9926590&icde=50457464."},{"key":"10.1016\/j.addr.2021.113849_b0955","unstructured":"https:\/\/projectreporter.nih.gov\/project_info_description.cfm?aid=9631401&icde=50448373."},{"key":"10.1016\/j.addr.2021.113849_b0960","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1056\/NEJMoa1506110","article-title":"Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women","volume":"375","author":"Baeten","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2021.113849_b0965","doi-asserted-by":"crossref","first-page":"e25634","DOI":"10.1002\/jia2.25634","article-title":"Greater dapivirine release from the dapivirine vaginal ring is correlated with lower risk of HIV-1 acquisition: a secondary analysis from a randomized, placebo-controlled trial","volume":"23","author":"Brown","year":"2020","journal-title":"J. Int. AIDS Soc."},{"key":"10.1016\/j.addr.2021.113849_b0970","unstructured":"https:\/\/www.who.int\/news\/item\/26-01-2021-who-recommends-the-dapivirine-vaginal-ring-as-a-new-choice-for-hiv-prevention-for-women-at-substantial-risk-of-hiv-infection. Accessed February 19, 2021."},{"key":"10.1016\/j.addr.2021.113849_b0975","doi-asserted-by":"crossref","first-page":"e0201952","DOI":"10.1371\/journal.pone.0201952","article-title":"Phase I trial of pod-intravaginal rings delivering antiretroviral agents for HIV-1 prevention: rectal drug exposure from vaginal dosing with tenofovir disoproxil fumarate, emtricitabine, and maraviroc","volume":"13","author":"Vincent","year":"2018","journal-title":"PLoS ONE"},{"key":"10.1016\/j.addr.2021.113849_b0980","doi-asserted-by":"crossref","first-page":"e1002655","DOI":"10.1371\/journal.pmed.1002655","article-title":"Safety and pharmacokinetics of single, dual, and triple antiretroviral drug formulations delivered by pod-intravaginal rings designed for HIV-1 prevention: A Phase I trial","volume":"15","author":"Vincent","year":"2018","journal-title":"PLoS Med."},{"key":"10.1016\/j.addr.2021.113849_b0985","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1093\/cid\/ciy652","article-title":"Phase 1 Pharmacokinetic Trial of 2 Intravaginal Rings Containing Different Dose Strengths of Vicriviroc (MK-4176) and MK-2048","volume":"68","author":"Liu","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.addr.2021.113849_b0990","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1093\/cid\/ciy653","article-title":"Phase 1 Safety and Pharmacokinetics Study of MK-2048\/Vicriviroc (MK-4176)\/MK-2048A Intravaginal Rings","volume":"68","author":"Hoesley","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.addr.2021.113849_b0995","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1093\/jac\/dks097","article-title":"Intravaginal ring delivery of tenofovir disoproxil fumarate for prevention of HIV and herpes simplex virus infection","volume":"67","author":"Mesquita","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.addr.2021.113849_b1000","doi-asserted-by":"crossref","first-page":"16145","DOI":"10.1073\/pnas.1311355110","article-title":"Intravaginal ring eluting tenofovir disoproxil fumarate completely protects macaques from multiple vaginal simian-HIV challenges","volume":"110","author":"Smith","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2021.113849_b1005","doi-asserted-by":"crossref","first-page":"6272","DOI":"10.1128\/AAC.01431-12","article-title":"A 90-day tenofovir reservoir intravaginal ring for mucosal HIV prophylaxis","volume":"56","author":"Johnson","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.addr.2021.113849_b1010","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03670355."},{"key":"10.1016\/j.addr.2021.113849_b1015","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1002\/jps.24154","article-title":"An intravaginal ring for the sustained delivery of antibodies","volume":"103","author":"Gunawardana","year":"2014","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2021.113849_b1020","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s13346-015-0273-8","article-title":"Sustained release of the candidate antiretroviral peptides T-1249 and JNJ54310516-AFP from a rod insert vaginal ring","volume":"6","author":"Murphy","year":"2016","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.addr.2021.113849_b1025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2019.02.003","article-title":"Vaginal rings with exposed cores for sustained delivery of the HIV CCR5 inhibitor 5P12-RANTES","volume":"298","author":"McBride","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2021.113849_b1030","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/nature10373","article-title":"Broad neutralization coverage of HIV by multiple highly potent antibodies","volume":"477","author":"Walker","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.addr.2021.113849_b1035","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.virol.2012.06.025","article-title":"Topical gel formulation of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 confers protection against HIV-1 vaginal challenge in a humanized mouse model","volume":"432","author":"Veselinovic","year":"2012","journal-title":"Virology"},{"key":"10.1016\/j.addr.2021.113849_b1040","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1146\/annurev-immunol-030409-101256","article-title":"The role of antibodies in HIV vaccines","volume":"28","author":"Mascola","year":"2010","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.addr.2021.113849_b1045","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ejpb.2010.10.010","article-title":"Sustained release of proteins from a modified vaginal ring device","volume":"77","author":"Morrow","year":"2011","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2021.113849_b1050","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jconrel.2016.04.035","article-title":"A novel approach to administration of peptides in women: Systemic absorption of a GnRH agonist via transvaginal ring delivery system","volume":"233","author":"Kimball","year":"2016","journal-title":"J. Control. Release"},{"issue":"Suppl. 4","key":"10.1016\/j.addr.2021.113849_b1055","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/hiv.12716","article-title":"Two-drug vs. three-drug combinations for HIV-1: Do we have enough data to make the switch?","volume":"20","author":"Moreno","year":"2019","journal-title":"HIV Med."},{"key":"10.1016\/j.addr.2021.113849_b1060","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1007\/s13346-017-0389-0","article-title":"An intravaginal ring that releases three antiviral agents and a contraceptive blocks SHIV-RT infection, reduces HSV-2 shedding, and suppresses hormonal cycling in rhesus macaques","volume":"7","author":"Derby","year":"2017","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.addr.2021.113849_b1065","doi-asserted-by":"crossref","first-page":"e0159332","DOI":"10.1371\/journal.pone.0159332","article-title":"A Novel Microbicide\/Contraceptive Intravaginal Ring Protects Macaque Genital Mucosa against SHIV-RT Infection Ex Vivo","volume":"11","author":"Villegas","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.addr.2021.113849_b1070","unstructured":"https:\/\/www.hiv-druginteractions.org\/interactions\/2562\/all. Accessed May 25, 2021."},{"key":"10.1016\/j.addr.2021.113849_b1075","article-title":"Randomized, placebo-controlled trial of safety, pharmacokinetics, and pharmacodynamics of 90-day intravaginal rings (IVRs) releasing tenofovir (TFV) with and without levonorgestrel (LNG) among women in Western Kenya","author":"Mugo","year":"2021","journal-title":"Abstract OA06.02, HIVR4P Virtual"},{"key":"10.1016\/j.addr.2021.113849_b1080","unstructured":"A. Thurman, V. Brache, A.L. Ouattara, N. Chandra, T. Jacot, S. Jackson, M. Clark, M.M. Peet, H. Hanif, T. McCormick, S. Ju, J.L. Schwartz, M. Marzinke, D.W. Erikson, U. Parikh, B.C. Herold, R.N. Fichorova, E. Tolley, G.F. Doncel, Randomized, Placebo Controlled Phase I Trial of Safety, Pharmacokinetics, Pharmacodynamics and Acceptability of a Multipurpose Prevention Vaginal Ring Containing Tenofovir and Levonorgestrel. Abstract OA06.03, HIVR4P,Virtual, 2021."},{"key":"10.1016\/j.addr.2021.113849_b1085","unstructured":"https:\/\/www.mtnstopshiv.org\/research\/studies\/mtn-030ipm-041, Accessed February 10, 2021."},{"key":"10.1016\/j.addr.2021.113849_b1090","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1097\/QAI.0000000000001455","article-title":"Brief Report: Dapivirine Vaginal Ring Use Does Not Diminish the Effectiveness of Hormonal Contraception","volume":"76","author":"Balkus","year":"2017","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.addr.2021.113849_b1095","doi-asserted-by":"crossref","DOI":"10.1089\/aid.2014.5273.abstract","article-title":"Drug-drug Interaction Studies Investigating the Impact of Levonorgestrel on Antiviral Potency of Dapivirine","author":"Evans","year":"2014","journal-title":"AIDS Research and Human Retroviruses, Poster A137"},{"key":"10.1016\/j.addr.2021.113849_b1100","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.actbio.2020.09.020","article-title":"Engineering tetravalent IgGs with enhanced agglutination potencies for trapping vigorously motile sperm in mucin matrix","volume":"117","author":"Shrestha","year":"2020","journal-title":"Acta Biomater."},{"key":"10.1016\/j.addr.2021.113849_b1105","unstructured":"https:\/\/reporter.nih.gov\/project-details\/9820191."},{"key":"10.1016\/j.addr.2021.113849_b1110","unstructured":"https:\/\/reporter.nih.gov\/project-details\/10018526."},{"key":"10.1016\/j.addr.2021.113849_b1115","unstructured":"https:\/\/www.theimpt.org\/resource-results\/35-reports\/202-assessing-the-potential-of-mpts-in-south-africa-uganda-and-nigeria. Accessed February 18, 2021."},{"key":"10.1016\/j.addr.2021.113849_b1120","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1089\/apc.2018.0177","article-title":"Design of an implant for long-acting HIV pre-exposure prophylaxis: input from South African Health Care Providers","volume":"33","author":"Krogstad","year":"2019","journal-title":"AIDS Patient Care STDs"},{"key":"10.1016\/j.addr.2021.113849_b1125","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1177\/0272989X17729376","article-title":"Divergent Preferences for HIV Prevention: A Discrete Choice Experiment for Multipurpose HIV Prevention Products in South Africa","volume":"38","author":"Quaife","year":"2018","journal-title":"Med. Decis. Making"},{"key":"10.1016\/j.addr.2021.113849_b1130","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1007\/s10461-019-02418-7","article-title":"Acceptability and Predictors of Uptake of Anti-retroviral Pre-exposure Prophylaxis (PrEP) Among Fishing Communities in Uganda: A Cross-Sectional Discrete Choice Experiment Survey","volume":"23","author":"Kuteesa","year":"2019","journal-title":"AIDS Behav."},{"key":"10.1016\/j.addr.2021.113849_b1135","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1007\/s10461-019-02715-1","article-title":"Efficacy is Not Everything: Eliciting Women's Preferences for a Vaginal HIV Prevention Product Using a Discrete-Choice Experiment","volume":"24","author":"Browne","year":"2020","journal-title":"AIDS Behav."},{"key":"10.1016\/j.addr.2021.113849_b1140","unstructured":"A. Minnis, J. Etima, M.K. Shapley-Quinn, P. Musara, D. Kemigisha, E. Browne, M. Stoner, N. Mgodi, C. Nakabiito, M. Hartmann, N. Macagna, J. Piper, A. van der Straten, Heterosexual couples' preferences for dual-purpose prevention products for HIV and pregnancy prevention: the CUPID Study (MTN-045) in Uganda and Zimbabwe, HIVR4P,Virtual, 2021."},{"key":"10.1016\/j.addr.2021.113849_b1145","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1007\/s10461-018-2078-5","article-title":"Young Women's Ratings of Three Placebo Multipurpose Prevention Technologies for HIV and Pregnancy Prevention in a Randomized, Cross-Over Study in Kenya and South Africa","volume":"22","author":"Minnis","year":"2018","journal-title":"AIDS Behav."},{"key":"10.1016\/j.addr.2021.113849_b1150","unstructured":"S. Nkomo, I. Mahaka, E. Luecke, A.v.d. Straten, M.K. Shapley-Quinn, W. Makoni, K. Ahmed, E. Mbatsane, L. Johnson, End-users' hypothetical acceptability of a biodegradable implant to prevent HIV and unplanned pregnancy: qualitative insights from South Africa and Zimbabwe, HIVR4PVirtual, 2021."},{"key":"10.1016\/j.addr.2021.113849_b1155","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.contraception.2017.10.006","article-title":"Interest in multipurpose prevention technologies to prevent HIV\/STIs and unintended pregnancy among young women in the United States","volume":"97","author":"Hynes","year":"2018","journal-title":"Contraception"},{"key":"10.1016\/j.addr.2021.113849_b1160","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1089\/jwh.2018.7001","article-title":"Preferred product attributes of potential multipurpose prevention technologies for unintended pregnancy and sexually transmitted infections or HIV among U.S. Women","volume":"28","author":"Hynes","year":"2019","journal-title":"J. Womens Health"},{"key":"10.1016\/j.addr.2021.113849_b1165","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1089\/apc.2020.0164","article-title":"A qualitative exploration of women's interest in long-acting injectable antiretroviral therapy across six cities in the women's interagency HIV study: intersections with current and past injectable medication and substance use","volume":"35","author":"Philbin","year":"2021","journal-title":"AIDS Patient Care STDs"},{"key":"10.1016\/j.addr.2021.113849_b1170","article-title":"Tenofovir-only and tenofovir\/levonorgestrel intravaginal rings are unlikely to impact the genital microbiota of sub-Saharan women, HIVR4P","author":"Dabee","year":"2021","journal-title":"Virtual"},{"issue":"Suppl. 5","key":"10.1016\/j.addr.2021.113849_b1175","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/1471-0528.12875","article-title":"Interest in multipurpose prevention of HIV and pregnancy: perspectives of women, men, health professionals and community stakeholders in two vaginal gel studies in southern Africa","volume":"121","author":"Woodsong","year":"2014","journal-title":"BJOG"},{"key":"10.1016\/j.addr.2021.113849_b1180","doi-asserted-by":"crossref","DOI":"10.1177\/2325958219841366","article-title":"Two birds with one stone: health care providers' perspectives about prevention technologies in Kenya and South Africa","volume":"18","author":"Lutnick","year":"2019","journal-title":"J. Int. Assoc. Provid. AIDS Care"},{"key":"10.1016\/j.addr.2021.113849_b1185","unstructured":"http:\/\/mpts101.org\/mpt-database\/product-page\/17-mpts\/systemic-mpts-oral\/145-dual-prevention-pill-dpp-regimen."},{"key":"10.1016\/j.addr.2021.113849_b1190","unstructured":"M.K. Shapley-Quinn, W. Makoni, E. Luecke, E. Mbatsane, E. Odoom, E. Krogstad, L. Johnson, A. van der Straten, End\u2010user research for the development of an implant to prevent unintended pregnancy and HIV prevention: qualitative insights from South Africa and Zimbabwe, Virtual, 23rd International AIDS Conference, 2020."}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X21002416?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X21002416?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T05:15:45Z","timestamp":1759209345000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X21002416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":238,"alternative-id":["S0169409X21002416"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2021.113849","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in long-acting injectables, implants, and vaginal rings for contraception and HIV prevention","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2021.113849","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"113849"}}